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Role of emotional processing in depressive responses to
sex-hormone manipulation: a pharmacological fMRI study
S Henningsson1,2, KH Madsen2,3, A Pinborg4,5, M Heede1, GM Knudsen1,5, HR Siebner1,2,5,6 and VG Frokjaer1
Sex-hormone ﬂuctuations may increase risk for developing depressive symptoms and alter emotional processing as supported by
observations in menopausal and pre- to postpartum transition. In this double-blinded, placebo-controlled study, we used
blood− oxygen level dependent functional magnetic resonance imaging (fMRI) to investigate if sex-steroid hormone manipulation
with a gonadotropin-releasing hormone agonist (GnRHa) inﬂuences emotional processing. Fifty-six healthy women were
investigated twice: at baseline (follicular phase of menstrual cycle) and 16 ± 3 days post intervention. At both sessions, fMRI-scans
during exposure to faces expressing fear, anger, happiness or no emotion, depressive symptom scores and estradiol levels were
acquired. The fMRI analyses focused on regions of interest for emotional processing. As expected, GnRHa initially increased and
subsequently reduced estradiol to menopausal levels, which was accompanied by an increase in subclinical depressive symptoms
relative to placebo. Women who displayed larger GnRHa-induced increase in depressive symptoms had a larger increase in both
negative and positive emotion-elicited activity in the anterior insula. When considering the post-GnRHa scan only, depressive
responses were associated with emotion-elicited activity in the anterior insula and amygdala. The effect on regional activity in
anterior insula was not associated with the estradiol net decline, only by the GnRHa-induced changes in mood. Our data implicate
enhanced insula recruitment during emotional processing in the emergence of depressive symptoms following sex-hormone
ﬂuctuations. This may correspond to the emotional hypersensitivity frequently experienced by women postpartum.
Translational Psychiatry (2015) 5, e688; doi:10.1038/tp.2015.184; published online 1 December 2015
INTRODUCTION
Mood disorders are among the most common causes for disability
and constitute a major and severe public health problem.1 The
prevalence is twice as high in women relative to men.2
Postpartum depression, premenstrual dysphoric disorder (PMDD)
and major depression with onset in the menopausal transition
phase are examples of mood disorders coinciding with ﬂuctua-
tions, or a rapid decline, in sex-steroid hormone levels. The
mechanisms underlying these phenomena are not well under-
stood, but may be related to neurobiological effects of changes in
ovarian sex steroids, in particular estradiol.3,4
Altered processing of emotional stimuli has been recognised as
a core cognitive abnormality in mood disorders, including major
depression, postpartum depression and PMDD.5–8 Comparisons
across menstrual cycle phases, associated with subtle variations in
sex-steroid hormone levels, that is, the follicular versus luteal
phases, have also suggested phase-speciﬁc variations in emotional
processing.8–12 However, those studies offer no consensus with
respect to the pattern of brain regions recruited differently across
menstrual cycle phases. Further, chronic states of ovarian sex-
steroid hormone downregulation, that is, with hormonal contra-
ception, have been associated with blunted amygdala responses
to negatively valenced emotional stimuli suggesting that such
longer-term ovarian hormone deprivation might evoke changes in
emotional processing.13
In addition to the coupling between sex-steroid hormones,
emotional processing and mood, this study is motivated by
frequent reports of a relationship between serotonergic transmis-
sion and emotional processing14–16 since sex steroids and
serotonin interact. This interaction is supported in particular by
rodent and non-human primate work of Bethea et al.17
Here we studied emotional processing before and after
manipulating ovarian sex-steroid hormone production by inter-
vention with the gonadotropin-releasing hormone agonist
(GnRHa) Goserelin. When administered continuously, GnRHa
initially stimulates and subsequently, after ~ 2 weeks, down-
regulates ovarian hormone production, in particular estradiol, by
desensitising GnRH receptors at the level of the pituitary gland. As
this intervention induces a transient ﬂuctuation in ovarian
hormones in healthy women, it can serve as a model for studying
the neurobiological correlates of such a ﬂuctuation and its
potential coupling to behavioural or psychological responses.
Using blood− oxygen level dependent (BOLD) functional mag-
netic resonance imaging (fMRI), we mapped functional brain
activation in emotion-related regions during implicit (gender
labelling) emotional processing of faces expressing fear, anger,
happiness and no emotion. Functional brain activity was
measured with fMRI at baseline and after intervention with either
GnRHa or placebo. The post-intervention session was placed
shortly after the biphasic GnRHa response in the early suppression
1Center for Integrated Molecular Brain Imaging and Neurobiology Research Unit, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark; 2Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Hvidovre Hospital, Hvidovre, Denmark; 3DTU Compute,
Technical University of Denmark, Lyngby, Denmark; 4The Fertility Clinic, Department of Obstetrics and Gynecology, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark; 5Faculty of Health and Medical Sciences, Copenhagen University Hospital, Copenhagen, Denmark and 6Department of Neurology, Bispebjerg Hospital, Copenhagen,
Denmark. Correspondence: Dr VG Frokjaer, Center for Integrated Molecular Brain Imaging and Neurobiology Research Unit, Rigshospitalet, Blegdamsvej 9, Copenhagen DK-2100,
Denmark.
Email: vibe@nru.dk
Received 1 June 2015; revised 29 September 2015; accepted 2 October 2015
Citation: Transl Psychiatry (2015) 5, e688; doi:10.1038/tp.2015.184
www.nature.com/tp
phase as motivated by studies documenting that risk for depression
in perimenopause is particularly associated with ﬂuctuations in
estradiol4 and peaks early (day 10–19) postpartum.18 We hypothe-
sised that GnRHa would induce changes in depressive symptoms in
a manner dependent on estradiol changes and emotion-elicited
brain activity.
MATERIALS AND METHODS
Participants, intervention and assessment timing
Participants were recruited by internet advertisements. Inclusion criteria
comprised regular menstrual cycles (duration 23–35 days) for at least
3 months before inclusion, normal hormone blood tests (including follicle-
stimulating hormone, thyroid-stimulating hormone and androgens) and
no history of neurological, gynaecological or psychiatric disorders,
including PMDD, as assessed by Schedules for Clinical Assessment in
Neuropsychiatry (SCAN 2.1) interview, as well as neurological and
gynaecological examinations including a transvaginal ultrasound of the
uterus and ovaries. Participants were enroled in the baseline assessment
program at a follicular phase cycle day and booked for their second
ultrasound examination at cycle day 21 or 22 to assure ovulation and
secure intervention timing to the midluteal phase as further detailed in
Frokjaer et al.19
Sixty-three healthy women participated in this randomised, placebo-
controlled and double-blinded intervention study. Participants received
3.6 mg GnRHa (Goserelin) implant (n=31) or saline injection (n=30) in a
natural cycle during the midluteal phase (cycle day 22.7 ± 2.7). Two
participants did not complete follow-up because of anovulation and
pregnancy, respectively. Three did not complete the follow-up MRI session
because of technical issues or personal matters. Two participants were
excluded from the placebo group owing to faulty cycle timing of the MRI
scan and failure to comply with the task, respectively. Thus valid fMRI data
from both sessions were available for 56 women (age 24.3 ± 5.0 years), 30
in the GnRHa group and 26 in the placebo group.
Baseline fMRI was acquired in the midfollicular phase (cycle day
6.0 ± 2.3) when ovarian hormone levels are most stable and the time
elapsed since the postovulatory estradiol drop is maximal. Follow-up fMRI
was acquired post bleeding at a time point late enough to allow the
GnRHa group to have entered their early ovarian suppression phase and
the placebo group to be in the follicular phase (16.0 ± 3 days after
intervention). This design allowed for all researchers to be blinded. See
Figure 1a for an outline of the time points. The participants also performed
other tasks in the scanner: the ﬁrst fMRI run comprised T1-weighted
imaging, resting state fMRI, a word memory fMRI paradigm, T2-weighted
imaging and diffusion tensor imaging. The second fMRI run, acquired after
a 40min break, comprised the emotional face fMRI paradigm reported
here and a gambling fMRI paradigm. Hamilton 17-item depression rating
scale and plasma concentrations of estradiol and progesterone were
collected within 0 ± 2 days from the fMRI session date at baseline and
follow-up. Estradiol and progesterone levels in serum were determined as
speciﬁed in ref. 19. Valid data on these measures were available for 29 and
26 subjects, respectively. The study was registered and approved by the
local ethics committee (H-2-2010-108). After complete description of the
study, written informed consent was obtained from all participants.
Experimental fMRI design
At baseline and follow-up, participants performed an emotional face
gender-labelling task, see ref. 20 and Figure 1b. Subjects were to indicate
the gender of photographs of faces with either fearful (F), angry (A), happy
(H) or neutral (N) expressions. The different conditions were presented in
blocks of six events, consisting of the block-speciﬁc expressions or null
events (ﬁxation crosses, one to three per block, pseudo-randomly
intermixed). Events lasted for 1 s and were interspersed with inter-
stimulus ﬁxation crosses presented for 1 s. The gender response button
rule (left or right for woman or man) was counterbalanced across subjects.
Participants were instructed to answer as fast and as correct as possible.
The testing was split up in two 7-min-long runs, each containing seven
blocks of each type. All photographs were presented only once. E-prime
software (Psychological Software Tools, Pittsburgh, PA, USA) was used for
stimulus presentation and response recordings.
Behavioural data analysis
Behavioural data were analysed using statistical parametric mapping
software package (SPSS, version 18, Chicago, IL, USA). Potential effects of
different emotional expressions on accuracy and reaction time (RT) at
baseline and at post intervention were examined by means of two
separate analysis of variance with emotion (F, A, H and N) as within-subject
factor (for the full sample). The intervention-related changes in accuracy
and RT were assessed using a two-way repeated measures analysis of
variance with emotion (Fpost−pre, Apost−pre, Hpost−pre, Npost−pre) as within-
subject factor and group (GnRHa versus placebo) as between-subject
factor. The Greenhouse-Geisser method was used to correct for non-
sphericity when appropriate.
Image acquisition
Images were acquired on a 3T Verio scanner with a 32-channel head array
coil (Siemens, Erlangen, Germany). For BOLD fMRI, a gradient echo based
Figure 1. (a) Timeline of the study program. Valid fMRI, estradiol and Hamilton depression rating scale (17 items) data for the baseline and
follow-up sessions were available for 29 subjects in the GnRHa group and 26 in the placebo group. Estradiol and Hamilton depression scores
were collected 0± 2 days within the fMRI day. (b) Example of the mode of presentation from a block of angry faces. CD, cycle day; fMRI,
functional magnetic resonance imaging; GnRHa, gonadotropin-releasing hormone agonist; ISI, inter-stimulus interval; p.i., post intervention.
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T2*-weighted gradient echo-planar imaging sequence was used with a
repetition time of 2.15 s, echo time of 26ms, ﬂip angle of 78°, and 42 slices
with a slice thickness of 3 mm with twofold acceleration using generalised
autocalibrating partially parallel acquisitions. The echo-planar imaging
sequence was optimised for signal recovery in orbitofrontal cortex.21 A
total of 198 whole-brain volumes were acquired in each session.
Imaging data analysis
The functional images were realigned, and normalised to an echo-planar
imaging template in Montreal Neurological Institute stereotactic space
using default SPM8 settings. The normalised images were smoothed using
an isotropic 8 mm Gaussian kernel. Analyses were conducted in SPM8.
For each voxel in the brain, a general linear model was constructed to
model event-related changes in the BOLD signal. At the within-subject
level, ﬁve event types were deﬁned for each fMRI session, which
corresponded to the presentation onsets for F, A, H and N faces, as well
as null events. RTs were modelled in a separate regressor in order to
control for differences in RT between different emotions. Incorrect answers
were excluded. The within-subject model also included 40 nuisance
regressors of no interest to account for variance in regional BOLD signal
changes caused by physiological noise, including head movement and
measurements of heart beat and respiration.22,23
Choosing a task where emotional faces could be contrasted with N faces
enabled isolation of emotion-speciﬁc brain activity. Within the ﬁrst-level
general linear model, we speciﬁed 3T-contrasts that captured differences
in the BOLD response to emotional as opposed to N images (F−N, A−N
and H−N, used as acronyms for the contrasts of interest hereafter) for
each participant, as well as contrasts comparing the post-intervention
images with the pre-intervention images (for example, post(F−N)−pre
(F−N)). Individual contrast images were entered into second-level analyses
for within-group and between-group statistical comparisons. On the
group-level (GnRHa versus placebo), the ﬁrst contrasts were used to
investigate the differential activation change from pre to post in the two
groups in a ﬂexible factorial design with group as between-subject factor
and pre/post as within-subject factor. Within the GnRHa group the latter
contrasts were used to investigate correlations between measures of
estradiol and depressive symptoms changes from baseline on the one
hand, and brain activity changes, on the other, in one-sample t-tests (two
sided). These analyses were contingent upon active intervention, which
introduced the expected biphasic estradiol change from baseline, and a
main effect of group on changes in Hamilton score.19
In line with results from previous studies,24,25 there was no signiﬁcant
test− retest correlation for amygdala activity in the placebo group for any
of the contrasts of interest (correlation coefﬁcients o0.3). This was the
case also for insula activity. Because of this lack of signiﬁcant test− retest
correlation, and because of previous ﬁndings of absolute levels of estradiol
being of less importance for mood than changes in levels,3 we also
considered it appropriate to test for the main effect of group (GnRHa
versus placebo) cross-sectionally at post intervention, as well as for a
potential relationship between activity in the post-GnRHa session and
estradiol and depressive symptoms changes, that is, not accounting for the
baseline fMRI measures. In this way we could also test if the baseline fMRI
measures were driving the observed effects. The relationship between
post-GnRHa depressive symptoms and post-GnRHa brain activity was also
investigated. When appropriate, the beta values of signiﬁcant peaks for
each subject were extracted in order to plot the value against changes in
estradiol or depression scores.
The general signiﬁcance level was set at Po0.05 for activation clusters
after correction for multiple non-independent comparisons using family
wise error correction. Our a priori primary region of interest (ROI) was the
amygdala, due to the well-documented involvement in mood.5–7
Secondary ROIs were the medial prefrontal cortex, including the medial
orbitofrontal cortex and the anterior cingulate cortex, the ventrolateral
prefrontal cortex (the sum of the Frontal_Inf_Tri and Frontal_Inf_Orb) as
well as insula, all deﬁned by the Pick atlas,26 based on previous reports
underscoring their relevance in emotional processing.27–30 We applied
small volume correction (SVC) using SPM8 for each of the ROIs to obtain
family wise error-corrected P-values based on Gaussian random ﬁelds.
Trends are reported at the cluster-forming threshold, which was set to
Punco0.001 (unc, uncorrected) for clusters consisting of at least ﬁve voxels.
Analyses of estradiol measures
Estradiol decline ‘dose-response’ analyses were considered appropriate in
the GnRHa group only. Changes in estradiol levels were treated as
Log2Estradiolpost–Log2Estradiolpre because of the lack of normal distribu-
tion for the raw delta values, as previously validated.19 Values below




As previously reported for the full sample,19 Goserelin initially
increased and subsequently reduced estradiol levels (from
0.18± 0.09 to 0.06± 0.04 nmol l–1), and led to an increase in
depressive symptoms on the Hamilton 17-item scale relative to
placebo (from 1.2 ± 1.6 to 3.0 ± 2.6, Po0.001). There was no net
decline in progesterone levels from baseline to follow-up (see ref.
19). The depressive symptoms were subtle except in two
participants who met the clinical criteria of a mild depressive
state. The magnitude of net estradiol decrease in response to
GnRHa and the emergence in depressive symptoms were
positively correlated (Pearson correlation= 0.39, P=0.04).
Both pre- and post-intervention, facial emotion was a signiﬁcant
within-subject factor on measures of accuracy and RT (Figures 2a
and b). The analyses of intervention-related changes in accuracy
revealed a group by pre−post interaction (F = 3.0, df= (3.0, 160.2),
P= 0.03), explained by an unexpected accuracy reduction (from
baseline) for A and N faces in the placebo group (Figures 2a and
b). Incorrect answers were excluded and RT was modelled in a
separate regressor for the fMRI analyses.
Imaging results
Main effects of treatment group. There was no signiﬁcant main
effect of treatment group (GnRHa versus placebo) nor a group by
pre/post-intervention interaction for the neural response to F, A or
H faces, as compared with N in any ROIs. No trends were observed
for the primary ROI amygdala, but for secondary ROIs a trend
(Punco0.001) for a larger increase in left perigenual anterior
cingulate cortex activity in the GnRHa group, compared with the
placebo group, was present for F and A faces (xyz= (−14 38 − 4),
peak Z-scores = 3.4). When considering only the post-intervention
session, relative to the placebo group, the GnRHa group tended
(Punco0.001) to show larger activity in the left anterior insula to A
faces post intervention (xyz= (–34 26 8), peak Z-score = 3.3,
PSVC = not signiﬁcant).
Correlations with depressive responses to GnRHa intervention.
Within the GnRHa group, individual increases in depressive
symptoms from baseline correlated signiﬁcantly with an increased
neural response in the insula ROI to F (left) and H (right) facial
expressions (F−N: xyz= (–32 16 0), peak Z-score = 3.6 PSVCo0.05,
H−N: xyz= (34 32 6), peak Z-score = 4.0 PSVCo0.001), with similar
but weaker trends for H faces in the contralateral hemispheres
(H−N xyz= (–26 22 –2), peak Z-score = 3.7, Punco0.001) and also
a trend (Punco0.001) bilaterally for A faces (A−N: xyz= (–26 26 –2),
peak Z-score = 3.6 and xyz= (34 32 4), peak Z-score= 3.3 PSVC-
values = not signiﬁcant). There was also a trend for a correlation
between depressive symptom increase and increased activity of
the right amygdala to H faces (xyz= (28 4 –16), peak Z-score = 3.3,
PSVC= 0.06). See Table 1 for details.
In the placebo group and for all of the three contrasts, there
was no signiﬁcant correlation between extracted activity within
the amygdala and insula pre- and post-intervention (Pearson
correlation coefﬁcients o0.3). In order to exclude that baseline
measures drove our results, an additional analysis based on neural
activity in the post-GnRHa session only was conducted. This
conﬁrmed that the increase in depressive symptoms correlated
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with F- and H-elicited activity in bilateral insula (F−N: xyz= (–34
16 –2), peak Z-score = 4.1, PSVCo0.001 and xyz= (32 36 0), peak
Z-score = 4.1, PSVCo0.05, Figure 3a, H−N: xyz= (–26 22 –2), peak
Z-score = 4.4, PSVCo0.001 and xyz= (32 22 –2), peak Z-score = 4.0,
PSVCo0.001, Figure 3b), and further correlated with F- and
H-elicited activity in the amygdala (F−N: xyz= (–24 2 –18), peak
Z-score = 3.5, PSVCo0.05, Figure 3a, H−N: xyz= (–26 0 –16),
peak Z-score = 3.7, PSVCo0.05, Figure 3b and xyz= (28 2 –14),
peak Z-score = 3.5, PSVCo0.05). There was a similar trend
(Punco0.001 for A faces within the right and left insula (xyz= (32
24 0), peak Z-score = 3.6 and xyz= (–26 26 –4), peak Z-score = 3.3)
but not in the amygdala (Punc40.05). See Table 1 for details. The
correlations between insula and amygdala activity and changes in
depressive scores remained signiﬁcant also after adjusting for
changes in estradiol levels.
When considering the relationship between brain activity at the
post-GnRHa session and absolute Hamilton scores (as opposed to
changes from baseline) for depressive symptoms at the post-
GnRHa session, similar patterns emerged, with signiﬁcant correla-
tions in bilateral insula and left amygdala (Table 1). In addition,
happiness-elicited activity in the supragenual anterior cingulate
cortex correlated with depressive symptoms (Table 1). Changes in
depressive symptoms correlated with depressive symptom scores
at the post-GnRHa session (Pearson correlation = 0.84, Po0.001).
Correlations with estradiol decline. Within the GnRHa group, the
net decline in estradiol levels across the intervention period
tended to correlate (Punco0.001) with an altered response of the
left ventrolateral prefrontal cortex to F faces (xyz= (–42 18 16),
peak Z-score = 3.7, PSVC = 0.12) from baseline. When considering
the post-GnRHa session only, no signiﬁcant correlations with the
magnitude of the estradiol decline (Punc40.001) were revealed.
This was the case also in a complete case analysis where the four
cases with estradiol values below detection limit were omitted, as
well as when estradiol measures were treated on the
absolute scale.
Imaging results at baseline. Pre-intervention, for the full sample,
A, but not F, faces elicited signiﬁcantly stronger left amygdala
activity than N faces (xyz= (–28 2 –22), peak Z-score = 3.6,
PSVCo0.05). Pre-intervention, H faces elicited signiﬁcant right
anterior insula activity (xyz= (44 18 –4), peak Z-score = 3.5,
PSVCo0.05), with a trend (Punco0.001) in the left insula as well
as for F and A faces. None of the ROIs displayed a signiﬁcant
correlation between activity to any of the emotional faces and
baseline estradiol levels (across groups). However, there was a
trend (Punco0.001) for a positive correlation between baseline
estradiol levels and activity to F and A faces in bilateral
ventrolateral prefrontal cortex (F−N: xyz= (–46 48 2), peak
Z-score = 3.7, PSVC = 0.07; A−N: xyz= (–52 36 22), peak Z-score =
3.6, PSVC = 0.09 and xyz= (56 40 12), peak Z-score = 3.8, PSVC =
0.06), with a similar trend for H faces.
DISCUSSION
The ovarian sex-steroid hormone manipulation affected processing
of emotional faces in a manner dependent on depressive
responses to the intervention. Women with a larger GnRHa-
induced depressive response had a larger increase in emotion-
elicited insula activity irrespective of emotional valence. When
only considering the post-GnRHa fMRI session, apart from
conﬁrming the insula ﬁnding, also amygdala recruitment was
associated with a larger depressive response. These ﬁndings were
not driven by baseline conditions, and the magnitude of the
Figure 2. (a) Accuracy. (b) Reaction times for the GnRHa (n= 30) and placebo (n= 26) groups pre- and post-intervention. Both pre- and post-
intervention, facial emotion was a signiﬁcant within-subject factor on measures of accuracy and RT (P-valueso0.001, FAccuracy_Pre= 41.8
df= (2.8, 153.5), FRT_Pre= 8.6, df= (2.8, 152.8), FAccuracy_Post= 44.9, df= (2.8, 153.8), FRT_Post= 6.6, df= (2.6, 147.3)). Accuracy was lower for F and
higher for H faces compared with N, whereas, as expected, RTs were slower for F and A faces compared with N and H faces (a and b). The
analyses of intervention-related changes in accuracy revealed a group by pre−post interaction, explained by an unexpected accuracy
reduction (from baseline) for A and N faces in the placebo group. Post hoc analyses showed that for angry faces there was also a signiﬁcant
baseline difference (placebo4GnRHa) between groups in accuracy (Punc= 0.04) that may partly have driven the interaction effect (a). There
was no Group by pre/post interaction on RT, indicating RTs were unaffected by GnRHa (F= 0.39, df= (2.8, 150.7), P= 0.74). Notably, there was a
slight non-signiﬁcant decrease in RT for both groups on the post-intervention session. A, angry; F, fearful; GnRHa, gonadotropin-releasing
hormone agonist; H, happy; N, neutral.
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GnRHa-induced net estradiol decline did not account for the
effects.
Our ﬁndings of changes in emotional processing may either be
directly pharmacologically driven or secondary to the (sub)clinical
depressive symptoms that may emerge in particularly sensitive
individuals. The absence of an association between GnRHa-
induced estradiol decline and emotion-probed brain activity that
map onto changes in depressive symptoms supports the latter.
However, it does not necessarily exclude that hormone ﬂuctua-
tions mediate the current ﬁndings. Since GnRHa induces a
biphasic ovarian hormone response, where the estradiol decline
is preceded by an augmentation, variability in the magnitude of
the initial augmentation may be of importance, as may inter-
individual variability in sensitivity either to the augmentation or to
the subsequent estradiol drop.12 If such increased estradiol
sensitivity would translate to an increased bottom-up engage-
ment of the insula and amygdala to emotional stimuli, our
ﬁndings would be compatible with the notion that the depressive
response is a consequence of the change in emotion processing.
Notably, previous studies in women show differences in sensitivity
to ﬂuctuations in estradiol to be critical for the development of a
depressed state; subjects with a history of depression have
increased risk of depression as a function of the estradiol
ﬂuctuations during menopausal transition,31 and, estradiol sensi-
tivity in late pregnancy, where sex-steroid levels are massively
increased, predicts postpartum depression.12,32,33 Thus, inter-
individual differences in the sensitivity to the same estradiol
changes may be of importance for the interpretation of the
current ﬁndings. Future studies should elucidate the importance
of an estradiol ﬂare and study relevant high-risk populations to
further explore the importance of estradiol sensitivity, for example,
by including biomarkers of sensitivity to sex steroids.
Our data suggest that, with increased depressive symptoms,
insula engagement when processing negative stimuli changed in
the same direction as that of positive stimuli. The fact that the
engagement of insula was independent of emotional valence is
well in line with previous studies suggesting that insula reacts to
both positive and negative stimuli.34,35 A core function of insula, in
particular the anterior portion, seems to be to facilitate bottom-up
detection of salient events that informs additional processing and
the generation of appropriate behavioural responses.36 The
positive correlation between insula activity change to emotional
stimuli and increase in depressive symptoms we observed is
consistent with some34,37,38 but not all39–41 studies. Previous
studies suggesting that insula function is sensitive to sex-steroid
hormone changes offer no consensus on directions. In healthy
individuals, left insula activity has been noted to be decreased in
response to negative emotional stimuli in the luteal phase of the
menstrual cycle.42 In contrast, a study in PMDD patients points
towards enhanced insula activation during response inhibition in
the symptomatic phase (luteal phase),43 which is well in line with
our observations.
We speculate that an increased insula engagement in proces-
sing of salient stimuli might represent a mechanism by which sex-
steroid hormone ﬂuctuations can trigger disturbed affective
processing and hence inﬂuence mood in vulnerable individuals.
It is possible that hyperreactivity to emotional salience is a
correlate to the postpartum blues state that occurs in most
women 3–5 days postpartum, which is characterized by dysphoric
mood, crying, mood lability, anxiety, irritability and a feeling of
easily being overwhelmed with emotions.44
When only the post-GnRHa session was considered, the
observation of higher activity in subjects with a larger increase
in depressive symptoms extended beyond the insula, and also
included our primary ROI, the amygdala. Thus, apparently, women
Table 1. Relationship: brain activity and GnRHa-induced depressive symptoms
Contrast Region Laterality Pa-value Z-score x y z
Correlation between increase in activity and increase in depressive symptoms
F−N Insula L Po0.05 3.6 − 32 16 0
A−N Insula L Punco0.001 3.1 − 26 26 − 2
R Punco0.001 3.3 34 32 4
H−N Insula L Punco0.001 3.7 − 26 22 − 2
R Po0.001 4.0 34 32 6
H−N Amygdala R Punco0.001 3.3 28 4 − 16
Correlation between activity post-GnRHa and increase in depressive symptoms
F−N Insula L Po0.001 4.1 − 34 16 − 2
R Po0.05 4.1 32 36 0
A−N Insula L Punco0.001 3.3 − 26 26 − 4
R Punco0.001 3.6 32 24 0
H−N Insula L Po0.001 4.4 − 26 22 − 2
R Po0.001 4.0 32 22 − 2
F−N Amygdala L Po0.05 3.5 − 24 2 − 18
H−N Amygdala L Po0.05 3.7 − 26 0 − 16
R Po0.05 3.5 28 2 − 14
Correlation between activity post-GnRHa and depressive symptoms post-GnRHa
F−N Insula L Po0.001 4.8 − 34 18 − 6
R Po0.001 4.1 48 12 − 4
A−N Insula L Po0.05 4.1 − 26 24 2
R Punco0.001 3.3 32 22 − 2
H−N Insula L Po0.001 4.8 − 38 − 4 − 10
R Po0.001 4.7 48 6 − 6
F−N Amygdala L Po0.001 3.8 − 24 2 − 18
H−N Amygdala L Po0.05 3.7 − 16 − 4 −18
H−N ACC supragenual Po0.05 3.7 2 24 24
Abreviations: A, angry; ACC, anterior cingulate cortex; F, fearful; GnRHa, gonadotropin-releasing hormone agonist; H, happy; N, neutral; unc, uncorrected.
aP-values are family wise error-corrected at cluster-level using small volume correction if not otherwise stated.
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who mood-wise were more vulnerable to GnRHa sex-hormone
manipulation displayed increased amygdala and insula involve-
ment in processing salient stimuli, independent of stimulus
valence. Several studies support that amygdala react to both
negative and positive stimuli.45–49 Hyperactivity of the amygdala
has also been reported in the luteal, as compared with the
follicular, phase of the menstrual cycle in healthy women when
estradiol levels are decreasing.6,11,50 In contrast to our GnRHa-
related ﬁndings, blunting of the amygdala response to aversive
stimuli has been reported to correlate with depression severity in
manifest postpartum depression.7 Since our model best matches
the onset of a depression and our participants only displayed
subtle and primarily subclinical depressive symptoms, our ﬁndings
are not directly comparable to the latter ﬁndings reported by
Moses-Kolko et al.7 However, our ﬁndings are in line with the
meta-analysis of Groenwold et al.5 that showed a correlation
between depressive response and amygdala activity elicited by
fearful stimuli, and suggest that such an effect is independent of
emotional valence. With regard to the increased amygdala activity
to happy faces in subjects with more GnRHa-induced depressive
symptoms, no clear consensus on potential differences between
controls and patients with major depression disorder exists.40,51,52
Although progesterone has also been linked to mood
sensitivtity and emotion-related brain activity, in particular in
PMDD,8 the absence of a net change in progesterone levels in the
current model19 prevented us from directly addressing potential
contributions from progesterone changes. Yet, within the GnRHa
framework we cannot ﬁrmly separate effects from different
ovarian-steroid hormones, for example, from the early stimulatory
phase of the GnRHa intervention. Future studies should address
the potential speciﬁcity of individual ovarian-steroid hormones in
the context.
Our study design does not allow a ﬁrm conclusion on whether
more complex neurobiological consequences of GnRHa interven-
tion may mediate the effects on insula and amygdala engagement
in processing of emotional salient stimuli. Potential mechanistic
factors can involve compromised serotonin signalling17,53 or
degradation of monoamines in general.12,54,55 We have previously
reported on an interaction between the magnitude of the
estradiol decline and increased serotonin transporter availability
on the depressive response to GnRHa based on molecular brain
imaging data within the present cohort.19 It is possible that inter-
individual variation in the inﬂuence of GnRHa on serotonergic
transmission, including effects of the initial stimulatory phase,
could explain the proposed variation in estradiol sensitivity. Such a
mechanism may well include serotonergic inﬂuence on amygdala
function,56 and will be further pursued in future studies. Further,
one might speculate that GnRHa could have a direct effect on
insula and/or amygdala activity. However, this is considered
unlikely since GnRH receptors are primarily expressed within the
Hypothalamus− Pituitary−Gonadal axis and particularly not in
Figure 3. Correlations in the GnRHa group (n= 29) between depressive symptom increase and activity in the insula and amygdala post-GnRHa
to (a) fearful and (b) happy faces, respectively, as compared with neutral faces. The mask used for visualisation includes the ﬁve bilateral ROIs.
GnRHa, gonadotropin-releasing hormone agonist; ROIs, region of interests.
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insula.57 Finally, it should be kept in mind that this study has not
yet been replicated.
In conclusion, our data demonstrate that enhanced recruitment
of the anterior insula and amygdala during emotional processing
have a role in the mechanism by which sex-hormone ﬂuctuations
trigger depressive symptoms, which may correspond to the
hypersensitivity to emotional stimuli frequently experienced by
women in perimenopause or the immediate postpartum period.
These ﬁndings may provide a rationale for future testing of
preventive strategies in high-risk individuals, for example, by
thorough monitoring of mental well-being during perimenopause
and in the immediate and early postpartum phase, and, to the
extent that extreme high-risk individuals can be identiﬁed,
possibly shorter term estradiol treatment in phases where women
decline rapidly or ﬂuctuate in ovarian sex-steroid levels.
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